Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Advancements in prognostic biomarkers for personalized therapy in multiple myeloma

Siobhan Glavey • 4 Nov 2022
Multiple Myeloma

Siobhan Glavey, MD, PhD, Royal College of Surgeons in Ireland, Dublin, Ireland, explains that molecular technologies have enabled the investigation of several prognostic biomarkers for multiple myeloma. Subsequently, this has aided in predicting survival outcomes and treatment response in patients with multiple myeloma. Prof. Glavey further discusses how the integration of these biomarkers into routine diagnostic strategies for multiple myeloma is needed to allow patients to receive more personalized therapies in the future. This interview was recorded virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Siobhan Glavey

1:16
The importance of treatment intensity in frail and elderly patients with multiple myeloma
Siobhan Glavey • 4 Nov 2022
1:52
The importance of onco-geriatric assessments for multiple myeloma
Siobhan Glavey • 4 Nov 2022
1:00
Understanding multiple myeloma heterogeneity by utilizing NGS
Siobhan Glavey • 4 Nov 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals